Gipr fl/fl within mGIPR-Ab treatment
The Orthopedic Clinics of North America
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
If you are currently taking semaglutide or tirzepatide, speak with your doctor about a safe transition plan
Othman, A
Funding The author(s) declare financial support was received for the research, authorship, and/or publication of this article